Keyword: Regulus Therapeutics

Regulus hopes for quick turnaround on FDA hold on hep C drug

Regulus Therapeutics saw its shares nosedive last month when the FDA put a clinical trial hold on its leading hep C candidate RG-101--but the company said this morning it hopes to get all of its ducks in a row for the FDA to lift the hold by the start of Q4.
MicroRNA

Regulus nabs $30M for fast hep C candidate

Small cap Regulus Therapeutics has nabbed a $30 million credit facility from Oxford Finance that it said is sufficient to get it into 2018. Most of the money is already earmarked to back its Phase II clinical program for lead candidate RG-101.